Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

null Ben Tran; L Horvath; M Rettig; K Fizazi; MP Lolkema; TB Dorff; Richard Greil; JPH Machiels; KA Autio; S Rottey; N Adra; R Garje; F Roncolato; ST Tagawa; SF Shariat; M Salvati; S Poon; H Kouros-Mehr

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran, L Horvath, M Rettig, K Fizazi, MP Lolkema, TB Dorff, Richard Greil, JPH Machiels, KA Autio, S Rottey, N Adra, R Garje, F Roncolato, ST Tagawa, SF Shariat, M Salvati, S Poon, H Kouros-Mehr

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	38
Issue number	15
Publication status	Published - 2020
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - ELECTR NETWORK Duration: 29 May 2020 → 31 May 2020

Cite this

Ben Tran, Horvath, L., Rettig, M., Fizazi, K., Lolkema, MP., Dorff, TB., Greil, R., Machiels, JPH., Autio, KA., Rottey, S., Adra, N., Garje, R., Roncolato, F., Tagawa, ST., Shariat, SF., Salvati, M., Poon, S., & Kouros-Mehr, H. (2020). Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY , 38(15).

Ben Tran ; Horvath, L ; Rettig, M et al. / Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY 2020 ; Vol. 38, No. 15.

@article{ec052d8104454d30a5afda1a9dbc54ef,

title = "Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).",

author = "{Ben Tran} and L Horvath and M Rettig and K Fizazi and MP Lolkema and TB Dorff and Richard Greil and JPH Machiels and KA Autio and S Rottey and N Adra and R Garje and F Roncolato and ST Tagawa and SF Shariat and M Salvati and S Poon and H Kouros-Mehr",

year = "2020",

language = "English",

volume = "38",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 29-05-2020 Through 31-05-2020",

}

Ben Tran, Horvath, L, Rettig, M, Fizazi, K, Lolkema, MP, Dorff, TB, Greil, R, Machiels, JPH, Autio, KA, Rottey, S, Adra, N, Garje, R, Roncolato, F, Tagawa, ST, Shariat, SF, Salvati, M, Poon, S & Kouros-Mehr, H 2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).', JOURNAL OF CLINICAL ONCOLOGY , vol. 38, no. 15.

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). / Ben Tran; Horvath, L; Rettig, M et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 38, No. 15, 2020.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

AU - Ben Tran, null

AU - Horvath, L

AU - Rettig, M

AU - Fizazi, K

AU - Lolkema, MP

AU - Dorff, TB

AU - Greil, Richard

AU - Machiels, JPH

AU - Autio, KA

AU - Rottey, S

AU - Adra, N

AU - Garje, R

AU - Roncolato, F

AU - Tagawa, ST

AU - Shariat, SF

AU - Salvati, M

AU - Poon, S

AU - Kouros-Mehr, H

PY - 2020

Y1 - 2020

M3 - Abstract (Journal)

SN - 0732-183X

VL - 38

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 29 May 2020 through 31 May 2020

ER -

Ben Tran, Horvath L, Rettig M, Fizazi K, Lolkema MP, Dorff TB et al. Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY . 2020;38(15).